{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.41","value":"23.8"},{"groupId":"OG001","spread":"4.20","value":"24.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"308"},{"groupId":"OG001","value":"311"}],"units":"Participants"}],"title":"Baseline, PWB subscale"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.71","value":"23.6"},{"groupId":"OG001","spread":"5.21","value":"23.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"225"}],"units":"Participants"}],"title":"End of Treatment, PWB subscale"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.82","value":"20.8"},{"groupId":"OG001","spread":"6.06","value":"20.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"310"},{"groupId":"OG001","value":"312"}],"units":"Participants"}],"title":"Baseline, SWB subscale"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.89","value":"20.2"},{"groupId":"OG001","spread":"5.34","value":"19.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"223"},{"groupId":"OG001","value":"223"}],"units":"Participants"}],"title":"End of Treatment, SWB subscale"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.20","value":"18.2"},{"groupId":"OG001","spread":"4.12","value":"18.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"311"},{"groupId":"OG001","value":"313"}],"units":"Participants"}],"title":"Baseline, EWB subscale"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.31","value":"18.7"},{"groupId":"OG001","spread":"4.67","value":"18.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"225"}],"units":"Participants"}],"title":"End of Treatment, EWB subscale"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.19","value":"17.3"},{"groupId":"OG001","spread":"6.08","value":"17.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"311"},{"groupId":"OG001","value":"312"}],"units":"Participants"}],"title":"Baseline, FWB subscale"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.29","value":"16.8"},{"groupId":"OG001","spread":"6.22","value":"16.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"224"}],"units":"Participants"}],"title":"End of Treatment, FWB subscale"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.91","value":"47.4"},{"groupId":"OG001","spread":"7.98","value":"47.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"310"},{"groupId":"OG001","value":"312"}],"units":"Participants"}],"title":"Baseline, FACT-LymS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.17","value":"48.7"},{"groupId":"OG001","spread":"8.71","value":"48.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"225"}],"units":"Participants"}],"title":"End of Treatment, FACT-LymS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.40","value":"88.7"},{"groupId":"OG001","spread":"15.72","value":"89.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"307"},{"groupId":"OG001","value":"309"}],"units":"Participants"}],"title":"Baseline, FACT-Lymphoma TOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.74","value":"89.0"},{"groupId":"OG001","spread":"18.14","value":"87.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"222"}],"units":"Participants"}],"title":"End of Treatment, FACT-Lymphoma TOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.39","value":"80.2"},{"groupId":"OG001","spread":"15.43","value":"79.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"308"},{"groupId":"OG001","value":"309"}],"units":"Participants"}],"title":"Baseline, FACT-G Total Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.65","value":"79.2"},{"groupId":"OG001","spread":"16.80","value":"77.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"223"},{"groupId":"OG001","value":"220"}],"units":"Participants"}],"title":"End of Treatment, FACT-G Total Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.18","value":"127.7"},{"groupId":"OG001","spread":"21.57","value":"127.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"307"},{"groupId":"OG001","value":"308"}],"units":"Participants"}],"title":"Baseline, FACT-Lymphoma Total Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.26","value":"127.8"},{"groupId":"OG001","spread":"24.18","value":"125.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"220"}],"units":"Participants"}],"title":"End of Treatment, FACT-Lymphoma Total Score"}],"denoms":[{"counts":[{"groupId":"OG000","value":"326"},{"groupId":"OG001","value":"328"}],"units":"Participants"}],"description":"The FACT-Lymphoma (v4) is composed of 42 items with a 5-point Likert-type scale and 5 subscales. Physical well-being (PWB) subscale: 7 items measured on 0- to 4-point scale; total score = 0-28. Social/family well-being (SWB) subscale: 7 items measured on 0- to 4-point scale; total score = 0-28. Emotional well-being (EWB) subscale: 6 items measured on 0- to 4-point scale; total score = 0-24. Functional well-being (FWB) subscale: 7 items measured on 0- to 4-point scale; total score = 0-28. Lymphoma (LymS) subscale includes 15 items; total score = 0-60. Three total scores can be derived by adding the subscales: FACT-Lymphoma Trial Outcome Index (TOI): (PWB score) + (FWB score) + (LymS score); total score = 0-116. FACT-G total score: (PWB score) + (SWB score) + (EWB score) + (FWB score); total score = 0-108. FACT-Lymphoma total score: (PWB score) + (SWB score) + (EWB score) + (FWB score) + (LymS score); total score = 0-168. The higher the score, the better the quality of life.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with FL and MZL were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG000","title":"FL and MZL: Tafasitamab + Rituximab + Lenalidomide"},{"description":"Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG001","title":"FL and MZL: Placebo + Rituximab + Lenalidomide"}],"paramType":"MEAN","populationDescription":"Overall Full Analysis Set. As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Only participants with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"up to approximately 34 months","title":"Overall Population: FACT-Lym Scores at Baseline and End of Treatment","type":"SECONDARY","unitOfMeasure":"scores on a scale"}